Unknown

Dataset Information

0

Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections.


ABSTRACT: Background: Evaluate the safety and efficacy of 104-week regimen of Telbivudine(LdT)-based optimization strategy for Chinese patients who have chronic hepatits B(CHB) with HBeAg-negative.

Methods: This multi-center, open-label, prospective study enrolled 108 HBeAg-negative CHB patients who received LdT (600?mg/day) for 24?weeks, Adefovir (ADV) was added if HBV DNA remained detectable at week 24, otherwise LdT was maintained to use until 104?weeks. HBV DNA, alanine amino transferase (ALT), hepatitis B surface antigen(HBsAg), creatinine kinase(CK), and estimated glomerular filtration rate (eGFR) were measured, safety was assessed.

Results: Eighty-eight patients (81%) had HBV-DNA undetectable at 24?weeks and maintained to receive LdT monotherapy until 104?weeks, whereas the other 20 patients had HBV-DNA detectable and ADV was used in combination. For all patients, 72% of patients reached ALT normalization at 24?weeks, which increased to 80% at 52?weeks and 104?weeks, respectively.. 81% of total patients had undetectable HBV-DNA at 24?weeks, 92% at 52?weeks, and 94% at 104?weeks. The HBsAg titre declined steadily from baseline to 104?weeks (3.62 vs. 2.98 log10 IU/mL, p?2, p?
Conclusions: LdT was well tolerated and effective, and 94% of patients achieved virological suppression after 104?weeks.

Trial registration: This study was registered in clinicaltrials.gov on January 31, 2012 and the ID No. was NCT01521975 .

SUBMITTER: Gan W 

PROVIDER: S-EPMC7720458 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections.

Gan Weiqiang W   Li Jianguo J   Zhang Chunlan C   Chen Xuefu X   Lin Chaoshuang C   Gao Zhiliang Z  

BMC infectious diseases 20201207 1


<h4>Background</h4>Evaluate the safety and efficacy of 104-week regimen of Telbivudine(LdT)-based optimization strategy for Chinese patients who have chronic hepatits B(CHB) with HBeAg-negative.<h4>Methods</h4>This multi-center, open-label, prospective study enrolled 108 HBeAg-negative CHB patients who received LdT (600 mg/day) for 24 weeks, Adefovir (ADV) was added if HBV DNA remained detectable at week 24, otherwise LdT was maintained to use until 104 weeks. HBV DNA, alanine amino transferase  ...[more]

Similar Datasets

| S-EPMC3563589 | biostudies-literature
| S-EPMC3587589 | biostudies-literature
| S-EPMC3585285 | biostudies-literature
| S-EPMC5114476 | biostudies-literature
| S-EPMC3563525 | biostudies-literature
| S-EPMC3888503 | biostudies-literature
| S-EPMC2716864 | biostudies-other
| S-EPMC3618368 | biostudies-literature
| S-EPMC4846711 | biostudies-literature
| S-EPMC8062913 | biostudies-literature